Plasma is defined as a part of blood, which is a clear, straw-colored fluid residue after red platelets, white blood cells, blood cells, and other cellular components got eliminated. Human blood consists of various proteins. A mixture of lipoproteins, glycoprotein’s, simple proteins, and other conjugated proteins are called plasma proteins. By replacing the plasma's missing or deficient proteins, Plasma protein therapies are used to treat the well-defined medical condition. Plasma protein therapeutics includes biological medicines, which are either infused or injected to treat life-threatening, chronic and genetic diseases. These plasma proteins will play an important role in blood clotting and also provides immunity against diseases.
The global plasma protein therapeutics market is anticipated to reach USD xx billion by 2026 and is expected to register x% CAGR over the forecast period. Increasing usage of the plasma proteins derived medicines worldwide, the introduction of new plasma-derived therapies, rising prevalence of life-threatening diseases of immune or neurological systems and infectious diseases like Rabies, Tetanus, Hepatitis A&B and varicella, and rising investment in R&D are the major driving factors of the global plasma protein market.
More than 250 products derived from plasma were found and the key players are depending on Immunoglobulin (IG), albumin, and factor VIII for driving the sales and profitability. C1 esterase inhibitor (Ruconest), Human glucocerebrosidase (Elelyso), VEGFR fc-fusion (Eylea), CTLA-4 Fc-fusion (Nulojix), Anti-IL-6 receptor (Actemra), Anti-CD30 (Adcetris) are some of the U.S FDA approved therapeutic proteins that are produced by using different protein engineering technologies. The Shire acquired Baxalta, has received US FDA approval to produce a gammagard liquid solution at its Covington, Georgia plant on 2018, approval of GamaSTAN from Grifols on 2018, approval of flexbumin from Takeda on 2109 are going to fuel the market growth. Thus, approvals of new plasma-derived therapies are expected to further fuel the demand for market growth. Developing countries like China and Brazil offer new investment avenues to the global market giants.
Moreover, there are a few restraints for the market, which includes stringent government policies, issues pertaining to reimbursement, complexity in manufacturing biologics, which may limit the growth of the market. With the technological advancements, the process involving fractionating the protein from plasma has become high-cost saving and efficient, which is also supposed to boost the global plasma protein therapeutics market. With increasing awareness among people about the blood donations and government initiatives, plasma-derived medicine market is anticipated to grow in the coming years at a significant rate.
The global plasma protein market is segmented on the basis of product type, application, and Region.
Based on product type: Coagulation factors, immunoglobulin, alpha-1 proteinase inhibitor, and albumin.
Based on the application: Hemophilia, idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, primary immunodeficiency disorder, and other indications.
Based on geographical region: North America, Asia-Pacific, Europe, Latin America, and Middle-East & Africa.
North America stood as a developed market for plasma protein therapeutic and is going to see quick growth in the future. Europe was the leading regional markets and is projected to show significant growth in the coming years. In Europe, these products are considered as non-prescription products that allow their widespread use. Asia Pacific plasma protein therapeutic market growth was expected to drive by the increase in awareness about blood donations. Latin America is known to be an important regional market and is expected to experience sensible growth over the forecast period. Thus, all the above-stated improvements are going to push the market growth in the future.
The report covers in-depth analysis of Global Plasma Proteins Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Hemophilia, idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, primary immunodeficiency disorder, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in Global Plasma Proteins Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.